How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan-Reference-Cited by-同舟云学术

How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan

Published:2022-03-28 Issue:5 Volume:113 Page:1771-1778
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Watanabe Tomone¹²^ORCID,Sugiyama Takehiro³⁴,Imai Kenjiro³,Higashi Takahiro¹²^ORCID

Affiliation:

1. Division of Health Services Research National Cancer Center Japan Tokyo Japan

2. Department of Cancer Health Services Research Graduate School of Medicine The University of Tokyo Tokyo Japan

3. Diabetes and Metabolism Information Center Research Institute National Center for Global Health and Medicine Tokyo Japan

4. Department of Health Services Research Faculty of Medicine University of Tsukuba Tsukuba Japan

Funder

National Cancer Center Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15322

Reference19 articles.

1. Follow the leader

2. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?

3. Pancreatic Cancer Action Network.Policy proposal: drug lag issues. (Japanese). Accessed January 24 2022.https://www.pancan.jp/index.php?option=com_content&view=article&id=331

4. Ministry of Health Labour and Welfare.Globalizing drug approval and development procedures (Japanese). Accessed January 24. 2022.https://www.mhlw.go.jp/wp/seisaku/jigyou/11jigyou01/dl/IV‐1‐7‐6.pdf

5. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States